TOKYO —

New research spearheaded by scientists at the Seaver Autism Center for Research and Treatment at Mount Sinai indicates that Phelan-McDermid syndrome (PMS) could be considerably more common than earlier estimates have suggested. The groundbreaking findings, recently published in the esteemed journal Autism Research, propose that the condition affects approximately 1 in every 7,300 individuals, a figure that dramatically reconfigures our understanding of PMS prevalence. This revised estimate has profound implications for diagnosis, research, and the development of targeted therapies.

Unveiling a Wider Spectrum: The Hidden Prevalence of Phelan-McDermid Syndrome

Phelan-McDermid syndrome is a complex genetic disorder characterized by a deletion or mutation within the SHANK3 gene, located on chromosome 22. This genetic anomaly can manifest in a wide array of medical, intellectual, and behavioral challenges, profoundly impacting the lives of affected individuals. A significant hallmark of PMS is its strong association with autism spectrum disorder (ASD), with the majority of individuals diagnosed with PMS also meeting the diagnostic criteria for ASD. Scientific understanding has long posited that alterations in the SHANK3 gene are a substantial contributor to ASD, accounting for as many as one percent of all autism spectrum disorder cases.

However, the true scope of PMS has remained elusive due to limitations in diagnostic accessibility and awareness. Previous prevalence estimates, often based on more limited datasets or clinical observations, suggested a much rarer occurrence. The latest comprehensive analysis from Mount Sinai, however, leverages a vast pool of genetic data, painting a picture of a condition that may be significantly underdiagnosed.

The Power of Big Data: Genetic Insights Redefine Prevalence

The ambitious undertaking to re-evaluate PMS prevalence involved a large-scale collaboration. Mount Sinai researchers partnered with leading genetic testing laboratories, prominent academic medical centers, and extensive autism research programs. This synergistic effort culminated in the examination of genetic data from nearly 180,000 individuals who had undergone genetic testing and had a diagnosis of autism.

The methodology employed was robust, combining and analyzing information drawn from ten distinct sources. These included major genetic testing providers such as GeneDx, Labcorp, and Ambry Genetics, alongside significant research initiatives like the SPARK research study and the Autism Sequencing Consortium. Furthermore, data from several major children’s hospitals across the nation contributed to the comprehensiveness of the dataset.

By meticulously analyzing this extensive genetic information, the research team was able to account for several crucial factors that influence prevalence estimates. These included the likelihood of undiagnosed cases within the population, inherent limitations in the sensitivity and scope of certain genetic testing methodologies, and critically, individuals with Phelan-McDermid syndrome who may not present with overt autism spectrum disorder characteristics, thus potentially being missed by ASD-focused screening.

After these critical adjustments, the researchers arrived at a compelling new prevalence estimate: 13.7 cases per 100,000 individuals. This translates to an estimated 1 in 7,300 people living with Phelan-McDermid syndrome. This figure represents a dramatic upward revision from prior understandings and suggests that, within the United States alone, potentially more than 45,000 individuals could be living with this genetic condition without a formal diagnosis.

Tess Levy, MSc, an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the first author of the published paper, highlighted the significant disparities driving this underdiagnosis. "The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy stated. "Families may also face insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene." This underscores a systemic challenge in accessing comprehensive genetic diagnostics, particularly for conditions that may not fit neatly into established diagnostic pathways.

The Imperative of Genetic Testing: A Gateway to Diagnosis and Treatment

The implications of this study extend far beyond mere epidemiological data. The researchers strongly advocate for broader and more consistent access to genetic testing, positing it as a critical tool for identifying individuals who currently lack a diagnosis and the associated support.

Dr. Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, a co-founder of the Autism Sequencing Consortium, and the senior author of the paper, emphasized the transformative power of genetic knowledge. "We recommend that every child with autism undergo genetic testing, because knowledge is power," Dr. Buxbaum asserted. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries." This perspective highlights how a diagnosis, rooted in genetic understanding, can unlock pathways to personalized interventions and therapeutic breakthroughs.

The research was generously supported by CureSHANK and Neuren Pharmaceuticals, organizations dedicated to advancing understanding and treatment for Phelan-McDermid syndrome. This study is recognized as one of the most comprehensive efforts to date to accurately estimate the prevalence of PMS.

Dr. Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, articulated the driving force behind their involvement. "Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative," Dr. Groth explained. "Patients cannot benefit from these advances if they never receive a diagnosis." This statement underscores the crucial link between diagnosis and access to emerging medical advancements.

A New Era of Therapeutic Development for PMS

The timing of these prevalence findings is particularly significant given the accelerating pace of research and development in the field of Phelan-McDermid syndrome. Several promising clinical trials are currently underway, employing precision medicine approaches that directly target the underlying biological mechanisms of the disorder. These trials represent a paradigm shift, moving away from broad symptom management towards interventions designed to address the root genetic cause.

For individuals with PMS and their families, obtaining a genetic diagnosis now holds a deeper significance. It is no longer solely about understanding the etiology of their symptoms. A formal genetic diagnosis can now serve as a key to unlocking access to specialized medical care tailored to the specific needs associated with PMS, participation in cutting-edge research studies, enrollment in clinical trials for novel therapies, connection with supportive patient advocacy networks, and crucially, the potential to benefit from disease-modifying treatments that were previously unimaginable.

Geraldine Bliss, Board Chair of CureSHANK, echoed the sentiment of many within the affected community. "This study confirms what many families, clinicians, and advocates have suspected for years," Bliss stated. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important." Her statement emphasizes the long-held suspicion of underdiagnosis and the urgent need for identification as treatment options mature.

The findings from the Mount Sinai study strongly reinforce CureSHANK’s ongoing advocacy for expanded access to genetic testing. They also align seamlessly with the objectives of "Start Genetic," a global awareness campaign designed to encourage patients, families, healthcare providers, and advocacy groups to prioritize genetic considerations in their diagnostic and treatment approaches. The overarching message is clear: the revolutionary advancements in precision medicine, which hold immense promise for rare genetic conditions, can only truly benefit patients once they have been accurately identified and diagnosed. Without a diagnosis, the pathway to life-changing therapies remains blocked.

Looking Ahead: Bridging the Diagnostic Gap and Accelerating Research

The implications of this research are far-reaching and multifaceted. For healthcare providers, it serves as a critical reminder to consider genetic testing more broadly, especially in individuals presenting with developmental delays, intellectual disabilities, and autism spectrum disorder, even in the absence of a clear family history. For families, it empowers them to advocate for comprehensive genetic evaluations for their children. For researchers and pharmaceutical companies, it provides a more accurate landscape for understanding the burden of PMS, enabling better-informed decisions regarding resource allocation for clinical trials and therapeutic development.

The increased prevalence estimate suggests a greater pool of individuals who could potentially benefit from emerging treatments. This also necessitates an expansion of support networks and educational resources for families navigating a PMS diagnosis. The collaborative nature of this study, bringing together academic institutions, commercial laboratories, and patient advocacy groups, sets a precedent for future research into rare genetic disorders.

As new treatments for PMS move through the clinical trial pipeline, the ability to accurately identify affected individuals becomes paramount. The "Start Genetic" campaign, supported by these findings, aims to embed genetic thinking into routine clinical practice. This shift has the potential to not only benefit those with PMS but also to accelerate the identification and treatment of other rare genetic conditions. The future of medicine increasingly lies in personalized approaches, and accurate genetic diagnosis is the foundational step in unlocking this potential for all patients. The Mount Sinai study marks a significant stride towards realizing this vision for the Phelan-McDermid syndrome community and beyond.